AbbVie Inc. $ABBV Stock Holdings Increased by CX Institutional

CX Institutional lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 30.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 85,402 shares of the company’s stock after purchasing an additional 20,097 shares during the quarter. CX Institutional’s holdings in AbbVie were worth $19,774,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the second quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. raised its holdings in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on ABBV. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. BMO Capital Markets raised their target price on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Guggenheim boosted their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Evercore ISI raised their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Finally, UBS Group started coverage on shares of AbbVie in a research note on Wednesday. They issued a “neutral” rating and a $240.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Trading Up 4.3%

NYSE ABBV opened at $233.65 on Thursday. The stock’s 50-day moving average price is $226.63 and its two-hundred day moving average price is $214.80. The company has a market cap of $412.95 billion, a PE ratio of 177.01, a PEG ratio of 0.94 and a beta of 0.36. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the firm posted $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Reports say AbbVie is in advanced talks to buy Revolution Medicines (market value ~ $16B), fueling speculation the deal would expand AbbVie’s oncology pipeline and justify a premium valuation. AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: Market reaction reinforced the takeover narrative: Revolution Medicines and AbbVie shares rallied on takeover reports, as investors priced in strategic oncology upside and potential deal synergies. AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition
• Positive Sentiment: AbbVie expanded its ovarian‑cancer pipeline with a Phase 1, first‑in‑human ABBV‑901 trial update — a near‑term clinical development item that supports growth narrative beyond immunology specialties. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Neutral Sentiment: Ironwood’s surprise guidance and its LINZESS list‑price cut (AbbVie is the commercial partner) reshaped revenue/rebate dynamics for that franchise — a development that may indirectly affect AbbVie’s commercial results but whose net impact on ABBV is ambiguous. Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating (ABBV)
• Neutral Sentiment: AbbVie scheduled its full‑year and Q4 2025 earnings release and conference call for Feb. 4 — a date investors will watch for guidance and clarity on growth drivers and any commentary on M&A. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: A UBS analyst reiterated a Hold rating, noting AbbVie’s premium valuation and long‑duration growth but a balanced risk/reward — a reminder some analysts view upside as tied to execution and potential M&A. AbbVie: Premium Valuation, Strong Long-Duration Growth, but Balanced Risk/Reward Supports Hold Rating
• Negative Sentiment: AbbVie denied media reports that it was in talks to buy Revolution Medicines, which could remove the acquisition catalyst and lead to some profit‑taking after the initial rally. AbbVie denies media reports of talks to buy Revolution Medicines

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.